DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Programs to Support You During Chemotherapy (Pro-You)

Not Applicable

Completed

Conditions: Depressive Symptoms
Psychosocial Effects of Cancer and Its Treatment
Stage IIIA Rectal Cancer
Stage IVA Rectal Cancer
Fatigue
Stage IIA Rectal Cancer
Stage IIA Colon Cancer
Stage IIB Colon Cancer
Stage IIB Rectal Cancer
Stage IIC Colon Cancer

Interventions: Behavioral: Yoga Skills Training (YST)
Other: questionnaire administration
Other: psychological stress assessment
Other: fatigue and depressive symptom assessment and management
Other: laboratory biomarker analysis
Other: Attention Control

First Posted Date: 2014-05-28

Last Posted Date: 2015-06-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 3

Registration Number: NCT02148406

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

3-Tesla MRI Response to TACE in HCC (Liver Cancer)

Not Applicable

Terminated

Conditions: Advanced Adult Primary Liver Cancer
Adult Primary Hepatocellular Carcinoma
Localized Resectable Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Stage A Adult Primary Liver Cancer (BCLC)
Stage B Adult Primary Liver Cancer (BCLC)

Interventions: Device: 3 Tesla Magnetic Resonance Imaging
Drug: Magnevist® (Intravenous (IV) administration of MRI contrast agent)

First Posted Date: 2014-02-07

Last Posted Date: 2018-07-11

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 2

Registration Number: NCT02057874

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

3T MRI Biomarkers of Glioma Treatment Response

Early Phase 1

Terminated

Conditions: Adult Anaplastic Ependymoma
Adult Gliosarcoma
Adult Anaplastic Astrocytoma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Anaplastic Oligodendroglioma
Recurrent Adult Brain Tumor

Interventions: Device: 3-Tesla magnetic resonance imaging
Device: CEST-MRI
Device: DW-MRI
Device: DCE-MRI
Device: DSC-MRI
Drug: IV administration of gadolinium-containing contrast agent

First Posted Date: 2013-11-27

Last Posted Date: 2017-04-17

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 7

Registration Number: NCT01996527

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors

Not Applicable

Completed

Conditions: Head Neck Cancer

Interventions: Other: Baseline Study Measures
Behavioral: Yoga Evaluation
Behavioral: Yoga Program
Behavioral: Yoga Practice Plan
Other: Study Assessments

First Posted Date: 2013-09-27

Last Posted Date: 2016-04-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 40

Registration Number: NCT01951664

Locations: 🇺🇸
Vanderbilt University School of Nursing, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer

Not Applicable

Terminated

Conditions: Breast Cancer

Interventions: Procedure: high field strength magnetic resonance imaging
Procedure: magnetic resonance spectroscopic imaging
Procedure: chemical exchange saturation transfer magnetic resonance imaging
Procedure: diffusion-weighted magnetic resonance imaging
Procedure: dynamic contrast-enhanced magnetic resonance imaging

First Posted Date: 2013-09-10

Last Posted Date: 2016-08-03

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 3

Registration Number: NCT01938651

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Phase 2

Withdrawn

Conditions: Stage IV Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer

Interventions: Drug: pemetrexed disodium
Drug: carboplatin
Drug: cisplatin
Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2013-08-23

Last Posted Date: 2015-07-13

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT01928160

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Triple Negative Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
Triple-negative Breast Cancer
Estrogen Receptor Negative Breast Cancer

Interventions: Drug: cisplatin
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI
Drug: GDC -0941

First Posted Date: 2013-08-07

Last Posted Date: 2017-06-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 11

Registration Number: NCT01918306

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
Georgetown University, Washington, D.C., District of Columbia, United States

and more 13 locations

ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients

Not Applicable

Completed

Conditions: Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Dietary Supplement: nutritional intervention
Behavioral: exercise intervention
Other: follow-up care
Behavioral: counseling intervention
Other: quality-of-life assessment
Other: laboratory biomarker analysis
Other: questionnaire administration

First Posted Date: 2013-07-17

Last Posted Date: 2018-05-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 33

Registration Number: NCT01901367

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma

Phase 1

Completed

Conditions: Malignant Glioma

Interventions: Drug: Bevacizumab
Drug: Temozolomide
Dietary Supplement: Vitamin C

First Posted Date: 2013-07-03

Last Posted Date: 2022-03-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 14

Registration Number: NCT01891747

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

Not Applicable

Terminated

Conditions: Paget's Disease
Osteosarcoma
Ewing Sarcoma

Interventions: Other: DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI

First Posted Date: 2013-06-20

Last Posted Date: 2017-05-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 6

Registration Number: NCT01882231

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy